Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
InnoSweet
- Development stage
- Preclinical
- Lead developer
- Advenion
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
InnoSweet is a natural nutraceutical blend developed by Advenion Biotech, consisting of glucose, fructose, and D-pinitol. It is designed to modulate carbohydrate metabolism and insulin signaling pathways. D-pinitol, a key component of the blend, acts to reduce plasma glucose peaks and mitigate the adverse effects of fructose on liver metabolism, such as oxidative stress and lipid synthesis. By favoring fat oxidation and preventing the development of insulin resistance, the supplement is intended for the management of Type 2 Diabetes, insulin resistance, and hepatic steatosis.
- Brand names
- InnoSweet
- Other names
- D-Pinitol + Glucose + Fructose blend
Beyond the preview
Go deeper on InnoSweet.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on InnoSweet.